Home/Biorevert/Jae Il Joo, PhD
JI

Jae Il Joo, PhD

CTO

Biorevert

Therapeutic Areas

Biorevert Pipeline

DrugIndicationPhase
BRVT101Hepatocellular carcinomaPreclinical
BRVT121Hepatocellular carcinomaPhase I
BRVT151Hepatocellular carcinomaPhase I
BRVT221Non‑small‑cell lung cancer (I/O)Preclinical
BRVT321Colorectal cancerPreclinical
BRVT301Colorectal cancerPreclinical